Stock Library / JAZZ

JAZZ Unclassified Latest YouTube: Q2 2026 Published 2026-08-04

JAZZ

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

JAZZ (Jazz Pharmaceuticals): The EPS ’Miss’ Was a $77M Check It Won’t Add Back — Q2 2026

Published 2026-08-04

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-04

Podcast available

Yes

Current price

$261.62

+5.12 (+2.00%)

Trailing / Forward P/E

2616.20x

Forward: 10.15x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

15.5%

Earnings: —

Margins

26.9% op

Gross: 91.0% · Net: 20.4%

Balance sheet

1.78x current

Debt / Equity: 91.5

52-week range / Beta

$105.00 - $262.00

Beta: —

Analyst target

$266.90

Upside: 2.0%

Cash / shareholder return

8.38% FCF yield

Dividend yield: —

Company context

Industry: Biotechnology

Country: Ireland

Employees: —

Price to book: 3.62x

Return on equity: 22.1%

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Price chart

Market context for JAZZ

Competitive view

JAZZ vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

JAZZ latest YouTube video thumbnail

JAZZ

JAZZ

YouTube Podbean

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

SS&C Technologies Holdings Inc. latest YouTube video thumbnail

SS&C Technologies Holdings Inc.

SSNC

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

Palantir Technologies latest YouTube video thumbnail

Palantir Technologies

PLTR

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Expect a more volatile ride than the market average; that can amplify upside, but drawdowns can come fast too.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

JAZZ

$16.98B

JAZZ

SSNC

$19.02B

SS&C Technologies Holdings Inc.

PLTR

$390.88B

Palantir Technologies

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

JAZZ

2616.2x

JAZZ

SSNC

22.8x

SS&C Technologies Holdings Inc.

PLTR

182.8x

Palantir Technologies

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

JAZZ

10.2x

JAZZ

SSNC

10.5x

SS&C Technologies Holdings Inc.

PLTR

77.7x

Palantir Technologies

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

JAZZ

15.5%

JAZZ

SSNC

10.3%

SS&C Technologies Holdings Inc.

PLTR

84.7%

Palantir Technologies

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

JAZZ

—

JAZZ

SSNC

34.7%

SS&C Technologies Holdings Inc.

PLTR

325.0%

Palantir Technologies

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

JAZZ

26.9%

JAZZ

SSNC

24.6%

SS&C Technologies Holdings Inc.

PLTR

46.2%

Palantir Technologies

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

JAZZ

91.0%

JAZZ

SSNC

48.1%

SS&C Technologies Holdings Inc.

PLTR

84.1%

Palantir Technologies

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

JAZZ

20.4%

JAZZ

SSNC

13.2%

SS&C Technologies Holdings Inc.

PLTR

43.7%

Palantir Technologies

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

JAZZ

22.1%

JAZZ

SSNC

12.6%

SS&C Technologies Holdings Inc.

PLTR

32.6%

Palantir Technologies

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

JAZZ

8.4%

JAZZ

SSNC

6.8%

SS&C Technologies Holdings Inc.

PLTR

0.5%

Palantir Technologies

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

JAZZ

91.53x

JAZZ

SSNC

115.90x

SS&C Technologies Holdings Inc.

PLTR

2.48x

Palantir Technologies

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

JAZZ

1.78x

JAZZ

SSNC

1.06x

SS&C Technologies Holdings Inc.

PLTR

6.91x

Palantir Technologies

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

JAZZ

—

JAZZ

SSNC

1.09

SS&C Technologies Holdings Inc.

PLTR

1.56

Palantir Technologies

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

JAZZ

—

JAZZ

SSNC

1.4%

SS&C Technologies Holdings Inc.

PLTR

—

Palantir Technologies

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

JAZZ

2.0%

JAZZ

SSNC

13.9%

SS&C Technologies Holdings Inc.

PLTR

14.2%

Palantir Technologies

Related research

Non-quarter videos featuring JAZZ

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-04

JAZZ: The EPS 'Miss' Was a $77M Check It Won't Add Back #shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for JAZZ

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-04

Published youtube podcast complete

JAZZ (Jazz Pharmaceuticals): The EPS ’Miss’ Was a $77M Check It Won’t Add Back — Q2 2026

Quarterly earnings-analysis entry for JAZZ. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music